Search

Author/Creator Zhang, Joshua

3. Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma. Issue 1 (11th December 2019)

Authors:
Wang, Rui; Zheng, Junying; Shao, Xiao; Ishii, Yuko; Roy, Amit; Bello, Akintunde; Lee, Richard; Zhang, Joshua; Wind-Rotolo, Megan; Feng, Yan
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 7:Issue 1(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Loss of Reg proteins' protection of islet β cells in chronic pancreatitis: A potential mechanism for the pathogenesis of type 3c diabetes. (March 2019)

Authors:
Huan, Chongmin; Stanek, Albert; Mueller, Cathy; Ou, Peiqi; Dong, Sue; Zhang, Joshua; Abdel-Naby, Ramy; Gruessner, Rainer
Journal:
Current opinion in endocrine and metabolic research
Issue:
Volume 5(2019)
Page Start:
21
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. MT-PCR panel detection of canine parvovirus (CPV-2): Vaccine and wild-type CPV-2 can be difficult to differentiate in canine diagnostic fecal samples. (June 2017)

Authors:
Meggiolaro, Maira N.; Ly, Anna; Rysnik-Steck, Benjamin; Silva, Carolina; Zhang, Joshua; Higgins, Damien P.; Muscatello, Gary; Norris, Jacqueline M.; Krockenberger, Mark; Šlapeta, Jan
Journal:
Molecular and cellular probes
Issue:
Volume 33(2017)
Page Start:
20
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Issue 7 (July 2022)

Authors:
Motzer, Robert J; Powles, Thomas; Burotto, Mauricio; Escudier, Bernard; Bourlon, Maria T; Shah, Amishi Y; Suárez, Cristina; Hamzaj, Alketa; Porta, Camillo; Hocking, Christopher M; Kessler, Elizabeth R; Gurney, Howard; Tomita, Yoshihiko; Bedke, Jens; Zhang, Joshua; Simsek, Burcin; Scheffold, Chris...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 7(2022)
Page Start:
888
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial. (December 2022)

Authors:
Apolo, Andrea B.; Powles, Thomas; Escudier, Bernard; Burotto, Mauricio; Zhang, Joshua; Simsek, Burcin; Scheffold, Christian; Motzer, Robert J.; Choueiri, Toni K.
Journal:
European journal of cancer
Issue:
Volume 177(2022)
Page Start:
63
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. Issue 2 (February 2022)

Authors:
Cella, David; Motzer, Robert J; Suarez, Cristina; Blum, Steven I; Ejzykowicz, Flavia; Hamilton, Melissa; Wallace, Joel F; Simsek, Burcin; Zhang, Joshua; Ivanescu, Cristina; Apolo, Andrea B; Choueiri, Toni K
Journal:
Lancet oncology
Issue:
Volume 23:Issue 2(2022)
Page Start:
292
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. PD10-01 DISEASE-FREE SURVIVAL WITH LONGER FOLLOW-UP FROM THE CHECKMATE 274 TRIAL OF ADJUVANT NIVOLUMAB IN PATIENTS AFTER SURGERY FOR HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA. (May 2022)

Authors:
Galsky, Matthew; Witjes, Johannes Alfred; Gschwend, Jürgen E.; Schenker, Michael; Valderrama, Begoña P.; Tomita, Yoshihiko; Bamias, Aristotelis; Lebret, Thierry; Shariat, Shahrokh F.; Park, Se Hoon; Agerbaek, Mads; Jha, Gautam; Stenner, Frank Stenner; Collette, Sandra; Unsal-Kacmaz, Keziban; Nasr...
Journal:
Journal of urology
Issue:
Volume 207(2022)Supplement 5
Page Start:
e183
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial. Issue 9 (14th September 2022)

Authors:
George, Daniel J; Spigel, David R; Gordan, Lucio N; Kochuparambil, Samith T; Molina, Ana M; Yorio, Jeff; Rezazadeh Kalebasty, Arash; McKean, Heidi; Tchekmedyian, Nishan; Tykodi, Scott S; Zhang, Joshua; Askelson, Margarita; Johansen, Jennifer L; Hutson, Thomas E
Journal:
BMJ open
Issue:
Volume 12:Issue 9(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗